{
    "id": 4486,
    "name": "malignant biphasic mesothelioma",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:4486",
    "evidence": [
        {
            "id": 7344,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of sEphB4-HSA and Avastin (bevacizumab) resulted in tumor regression in an EPHB4-over expressing xenograft model of biphasic mesothelioma, and demonstrated improved efficacy over either agent alone (PMID: 23721559).",
            "molecularProfile": {
                "id": 16746,
                "profileName": "EPHB4 over exp"
            },
            "therapy": {
                "id": 4467,
                "therapyName": "Bevacizumab + sEphB4-HSA",
                "synonyms": null
            },
            "indication": {
                "id": 4486,
                "name": "malignant biphasic mesothelioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3429,
                    "pubMedId": 23721559,
                    "title": "EphB4 as a therapeutic target in mesothelioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23721559"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02798536",
            "title": "Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6800,
                    "therapyName": "LMB-100",
                    "synonyms": null
                },
                {
                    "id": 6816,
                    "therapyName": "LMB-100 + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03436732",
            "title": "Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 6802,
                    "therapyName": "LMB-100 + SVP-rapa",
                    "synonyms": null
                }
            ]
        }
    ]
}